It is important to approach emerging data with appropriate caution
Older weight loss medications would rarely result in more than 5% of weight loss from baseline and are typically not recommended to be taken for longer than three months
Any deviation from licensed dosing regimens should only occur under close medical supervision, as the risk-benefit profile at sub-therapeutic doses remains poorly characterised
If we have a drug that is reducing the complications of diabetes and obesity, then there should be a decrease in the trajectory of health care spending. Jeffrey Singer Are GLP-1s Worth the Cost
With obesity linked to hypertension, dyslipidemia, sleep apnea, cardiovascular disease, fatty liver disease, and kidney complications, GLP-1 drugs have become platform therapies rather than single-indication products
Urgent policy consideration of affordability and access, coupled with strategies to improve treatment persistence, is essential if these therapies are to meaningfully impact Polands obesity burden.